Organisation paid for research Program year 2025 Source: CMS Open Payments

Tribe Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$605,836

90 payments

Through program year 2025, Tribe Clinical Research is reported as receiving $605,836 in research payments, across 90 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$405,573	51
2024	Research	$139,432	25
2023	Research	$42,713	11
2021	Research	$18,117	3

Breakdown

Who paid Research payments · program years 2021–2025

GlaxoSmithKline, LLC. $395,484 66 payments
Novartis Pharmaceuticals Corporation $126,856 1 payment
Moderna TX, Inc. $36,097 9 payments
Applied Therapeutics, inc. $20,744 7 payments
BioCryst Pharmaceuticals, Inc. $18,117 3 payments
Lumos Diagnostics, Inc. $6,000 2 payments
Pfizer Inc. $2,537 2 payments

Studies the money was for Research payments · program years 2021–2025

A Phase 3A, Observer-Blind, Randomized, Controlled Study to Demonstrat $239,016 37 payments
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $126,856 1 payment
A Phase III, Randomized, Controlled, Observer-Blind Study to Evaluate $40,722 2 payments
A Phase II, Single-Blind, Randomized, Controlled Study to Evaluate the $36,319 11 payments
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease $34,847 8 payments
A Phase 2, Randomized, Double-Blind, Multi-Dose, Dose Finding Study to $33,633 7 payments
A Phase 2, Randomized, Double-Blind, Multi-Dose, Dose Finding Studyto $21,499 2 payments
A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Dose Find $21,036 6 payments
Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy $20,744 7 payments
An Open-label Study to Evaluate the Long-term Safety of Daily Oral BCX7353 in Subjects With Type I and II Hereditary Angioedema $18,117 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.